2 result(s) displayed (1 - 2 of 2):

Glaxo chief JV'ing his way to profits (from Corporate Dealmaker)

After watching his rivals consolidate and generic competition squeeze the company's earnings, GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty started allying to expand in emerging markets and shift money from pharmaceuticals into vaccines and consumer businesses.The latest deal is a revenue-sharing agreement with India's Dr. Reddy's Laboratories Ltd. (NYSE:RDY),...

Posted on June 16, 2009 12:52 PM

Glaxo, Novartis, Roche, Lilly back same company (from Corporate Dealmaker)

In an interesting play, four rival drug giants are using their venture capital arms to back a company they think has come up with a major new class of therapeutics. Biotech company Aileron Therapeutics received financing from GlaxoSmithKline plc (NYSE:GSK), Novartis AG (NYSE:NVS), Roche Holding AG (SWX:ROG) and Eli Lilly...

Posted on June 8, 2009 3:30 PM